Maricann Group (CNSX:MARI – Get Free Report) has been assigned a $7.50 target price by investment analysts at National Bankshares in a report released on Thursday,BayStreet.CA reports. The firm currently has an “outperform” rating on the stock.
Separately, BMO Capital Markets raised their price objective on Maricann Group from $5.50 to $5.75 in a research report on Friday, November 29th.
View Our Latest Research Report on Maricann Group
Maricann Group Stock Performance
Maricann Group Company Profile
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company’s services a patient base with more than 8,000 registered patients.
Featured Articles
- Five stocks we like better than Maricann Group
- How to buy stock: A step-by-step guide for beginners
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to Short Nasdaq: An Easy-to-Follow Guide
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Maricann Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maricann Group and related companies with MarketBeat.com's FREE daily email newsletter.
